CPTech Politics page- U.S. Government/Pharmaceutical Industry
Center for Public Integrity Report, April 2007|
Documents from the Center for Responsive Politics|
Documents from Public Citizen|
- December 21, 2004. Report
The Bush Administration’s Drug Importation Task Force
Delivers Another Favor for the Prescription Drug Industry. Also, see the
- September 20, 2004. Press release.
PhRMA Appears to Have Funneled Up to $41 Million To “Stealth
PACs” to Help Elect a Drug Industry-Friendly Congress.
- June 23, 2004. Press release.
Drug Industry and HMOs Deployed an Army of Nearly 1,000 Lobbyists to
Push Medicare Bill, Report Finds.
- June 23, 2003. The Other Drug War 2003: Drug Companies Deploy an Army of
675 Lobbyists to Protect Profits.
- July 23, 2001.
The Other Drug War: Big Pharma’s 625 Washington Lobbyists.
- July 2000, Public Citizen's Congress Watch,
Addicting Congress Drug Companies' Campaign Cash & Lobbying Expenses
- June 26, 2000.
Prove It Isn't So, Sen. Ashcroft After Taking $50,000 from Schering-Plough, Voters Need Action to Prove Missouri's
Junior Senator Isn't Captured By Special Interests
- January 26, 2000.
PhRMA’s Secret Playbook: "Insider" Documents Show Prescription Drug Industry Continues
Campaign to Undermine Support for a Prescription Drug Benefit.
- September 30, 1999.
Schering-Plough Plows Ahead with High-Priced Lobbying Campaign for a Claritin Patent Extension .
- July 29, 1999.
Can Schering-Plough's Aggressive Lobbying Buy a Claritin Patent Extension?
Pushing Prescriptions: How the Drug Industry Sells Its Agenda at Your Expense
- This website is a project of the Center for Public Integrity.
- This website is a project of the Corporations, Health Care and Democracy Initiative
focused on the pharmaceutical industry.
- July 7, 2006. M. Asif Ismail for the Center for Public Integrity.
Drug Lobby Second to None -
How the pharmaceutical industry gets its way in Washington.
- December 14, 2004. PhRMA press release.
PhRMA Names Tauzin President, CEO.
- July 15, 2004. Institute for Public Accuracy.
Top Bush Administration Member on HIV-AIDS Policy
Also Heads Drug Industry Front Group Opposing Generics.
- June 22, 2004. Biotechnology Industry Organization press release.
BIO Announces New Food and Ag Executive Director.
- September 29, 2003. Joint statement from Health GAP, the Global AIDS Alliance,
Africa Action, and the Student Global AIDS Campaign.
AIDS Organizations Raise Grave Concerns in Anticipation of Ex-Pharma CEO's
Confirmation As Head of Bush AIDS Plan.
- July 11, 2003.
Talking points used by Big Pharma in killing the Kennedy Amendment to HR 1298.
HR 1298, the U.S. Leadership Against HIV/AIDS, Tuberculosis and Malaria Act, authorized funds
for the purchase of medicines. The Kennedy amendment would have directed the
spending on medicines to low-cost generics.
- March 27, 2003. Corporate Council on Africa.
Coalition of Non-Profits and Businesses to Lobby for President's
AIDS Relief Plan for Africa.
- March 11, 2003. USTR press release.
USTR Announces Personnel Appointments.
- February, 2003. American Association of Retired People.
Drug Industry Finances Nonprofit Groups That Claim to Speak
for Older Americans.
- July 13, 2001. Departments of Commerce, Justice, and State, the
Judiciary and Related Agencies Apporpriations Bill, FY2002.
Report 107-139. This is a long document. In the middle of it,
it mentions a $1,000,000 appropriation to the International
Intellectual Property Institute, run by former PTO Cheif Bruce Lehman.
- June 6, 2001. IFPMA press release.
IFPMA and World Bank Fellowship Appointment.
- Money Watch, October 6, 1999,
The FLO of Money.
- July 7, 2006. Medical News Today.
Pharmaceutical Industry Spent $800M on Lobbying Over 7 Years, Report States, USA.?
- January 3, 2005. Editorial in Newsday.
Tauzin Changes Sides.
- December 16, 2004. Robert Pear for the New York Times.
House's Author of Drug Benefit Joins Lobbyists.
- December 16, 2004. Judy Sarasohn for the Washington Post.
Tauzin to Head Drug Trade Group.
- December 15, 2004. Rueters.
Drug Lobby Group Taps Tauzin for Top Job.
- November 4, 2004. Scrip.
IFPMA to Reform its Structure to Imporive Lobbying Efforts.
- July 28, 2003. Donald McNeil for the New York Times.
From Eli Lilly to Front Line.
- February 9, 2004. Janet Hook for the L.A. Times.
Lobbyist Offers Make Jaws Drop -
When drug and movie industries try to recruit a top congressman, it's a
murky area for ethics.
- July 23, 2003. Jim VandeHei and Juliet Eilperin for the Washington Post.
Drug Firms Gain Church Group's Aid.
- July 2, 2003. Amy Goldstein and David Brown for the Washington Post.
Bush to Name Ex-Lilly CEO to Run AIDS Fund.
- June 19, 2003. Jim Lobe for One World News.
U.S. Conservatives Take Aim at NGOs.
- June 9, 2003. Editorial in the Washington Post.
Behind the Lobbying Curtain.
- June 1, 2003. Robert Pear for the New York Times.
Drug Companies Increase Spending to Lobby Congress and Governments.
- May 1, 2003. Jim VandeHei for the Washington Post.
Drug Firms Boost Bush's AIDS Plan.
- April 15, 2003. Richard Morin and Claudia Deane for the Washington Post.
For CSIS, It's OSI to the Rescue.
- April 8, 2003. Richard Morin and Claudia Deane for the Washington Post.
Irked Drug Industry May Pull Tank Funds.
- February 20, 2003. Bloomberg news.
Health Care Industry Spends the Most on U.S. Lobbying.
- February 13, 2003. Don Michak for the Journal Inquirer.
Pandering or protection? Johnson says Connecticut jobs behind
drug-patent support; critics say she's repaying drug companies for
- February 6, 2003. Tom Hamburger for the Wall Street Journal.
Campaign Funds Help Steer U.S. Stance on Drug Patents: After Aiding
Republicans, Drug Companies Prevail on Limiting Drugs to Poor Nations.
- February 10, 2003. Op-ed in Science by Daniel S. Greenberg.
A No-Show In Politics.
- January 16, 2003. Robert Cohen and Ed Silverman Newhouse News Service.
Drug Firms in Position to Cash Political Chips.
- December 9, 2002. The Washington Post.
Bush Picks CXS Corp. Cheif for Treasury.
- December 5, 2002. Associated Press.
About $1 Billion Was Spent on Political Ads in Midterm Elections;
Group Backed by Drug Cos. in Lead.
- November 29, 2002. Maureen Groppe for the Indianapolis Star.
Lilly, Other Drug Firms Find Friends in This Year's Congress.
- November 4, 2002. Greg Hitt for the Wall Street Journal.
Drug Makers Pour Ad Money Into Final Days of Campaign.
- October 22, 2002. Thomas Edsall for the Washington Post.
Drug Industry Financing Fuels Pro-GOP TV Spots.
- October 21, 2002. Merrill Goozner forthe American Prospect.
Drug Money: How PhRMA's front groups buy elections.
- October 20, 2002. Robin Toner for the New York Times.
Democrats See a Stealthy Drive By Drug Industry to Help Republicans.
- October 1, 2002. Peter Stone for the National Journal.
PhRMA Writes A Big Check to the NRCC.
- August 23, 2002. Melody Petersen for the New York Times.
CNN to Reveal When Guests Promote Drugs for Companies.
- November 4, 2001. Leslie Wayne and Melody Petersen for the New York Times.
A Muscular Lobby Tries to Shape Nation's Bioterror Plan.
- August 14, 2001. Jennifer Washburn for the American Prospect.
- July 20, 2001. Associated Press.
Rove's ties to pharmaceutical industry probed.
- April 9, 2001. Mike Allen in the Washington Post.
Gay Republican to Hold AIDS Post.
- February 13, 2001. Julian Borger form The Guardain.
Industry that stalks the US corridors of power
- January 27, 2001. Fred Charatan, British Medical Journal.
U.S. Companies Help Pay for Bush Inauguration
- June 26, 2000, Paul Kane, in Roll Call,
Hatch Admits He's 'Senator Anonymous'
- June 24, 2000, Jackie Judd and Carter M. Yang, in ABC News,
`Senator Anonymous' Revealed
- Multinational Monitor, May 1996,
Dennis DeConcini, a member of the S&L scandal's Keating Five gang, chaired a Senate committee that oversaw drug patents until retiring last year. He
swiftly moved to Parry & Romani Associates, a firm run by his former chief of staff, Romano Romani.
At his new home, DeConcini represents pharmaceutical makers like Pfizer, Genetech, Upjohn and Glaxo-Wellcome, the world's largest drug company.
Glaxo-Wellcome hired Parry & Romani to maintain a loophole in the GATT trade treaty that extends patents on drugs such as Glaxo's Zantac [see
"GATT Rx: Profit Overdose," Multinational Monitor, May 1995]. The loophole, which remains unclosed, is worth millions to DeConcini's client because
it prevents consumers from buying cheaper generic alternatives to Zantac for another two years.
Corrections or suggestions to Mike Palmedo
| CPT home page |
CPT Intellectual Property page |
CPT Health Care page |